Biotech Values

[biomaven0]

that third-party payers will be required to pay for Ponatinib no matter how expensive it may be because there is no alternative.

I'm not suggesting that if Ariad went crazy and starting charging say $1m/yr then refusal would not be possible, but if we assume they charge in the same ballpark as Sprycel/Tasigna ($85k/yr), then assuming no "death panel" type reform in the US healthcare system I think reimbursement is assured. The UK of course is a different matter - but then they don't currently pay for Sprycel or Tasigna either (on made-up grounds that efficacy is unproven).

If there is going to be major pushback on pricing for oncology drugs, then the whole space is a no-brain short.

Peter